Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC)

European Journal of Cancer

Volumn 36, Issue 2, 2000, Pages 183-193

  Langer, C J ^a   McAleer, C A ^a   Bonjo, C A ^a   Litwin, S ^a   Millenson, M ^b   Kosierowski, R ^a   Blankstein, K ^c   Alexander, R ^b   Ozols, R F ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c Hunterdon Medical Center   (United States)

^d Pinnacle Health System   (United States)

Author keywords

1 h Paclitaxel; Calvert formula; Carboplatin; Chemotherapy advanced; NSCLC

Indexed keywords

CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE;

EID: 0033952944     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00248-8     Document Type: Article

References (28)

1. Bonomi P, Kim K, Kisler J, Johnson D. An ECOG phase III trial. Cisplatin/etoposide vs paclitaxel/cisplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 1996, 15, A1145.
2. Wosniak A, Crowley J, Balcerzak SP, et al. Randomized phase III trial of cisplatin vs cisplatin plus navelbine in treatment of advanced non-small cell lung cancer: report of Southwest Oncology Group Study (SWOG-9308). Proc Am Soc Clin Oncol 1996, 15, 374A1110.
3. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995, 13, 1860-1870.
4. Langer CJ, Rosvold E, Millenson MM, et al. Paclitaxel by one or 24 hour infusion combined with carboplatin in advanced nonsmall cell lung cancer: a comparative analysis. Proc Am Soc Clin Oncol 1997, 16, A1625.
5. Hainsworth JD, Greco FA. Paclitaxel administered by 1-hour infusion: preliminary results of a phase I/II trial comparing two schedules. Cancer 1994, 74, 1377-1382.
6. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995, 13, 1609-1614.
7. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7, 1748-1756.
8. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16, 31-41.
9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5, 649-655.
10. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958, 53, 457-481.
11. Schiller M, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony stimu-lating factor in patients with advanced cancer. J Clin Oncol 1994, 2, 241-248.
12. Johnson DH, Paul DM, Hande KR, DeVore RF. Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial LUN-46. Semin Oncol 9, 22(Suppl. 9), 30-33.
13. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1996, 14, 2054-2060.
14. Belani C, Aisner J, Hiponia D, Engstrom C. Paclitaxel and carboplatin with or without filgastrim support in patients with metastatic non-small cell lung cancer. Semin Oncol 1995, 22(Suppl. 9), 7-12.
15. Vafai D, Israel V, Zaretsky S, et al. Phase I/II trial of combination carboplatin and taxol in non-small cell lung cancer. Proc Am Soc Clin Oncol 1995, 14, A1067 (abstract).
16. Rowinsky EK, Flood WA, Sartorius SE, et al. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin Oncol 1995, 22(Suppl. 9), 48-54.
17. Bunn PA, Kelly K. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center Study. Semin Oncol 1995, 22(Suppl. 9), 2-6.
18. Giaccone G, Huizing M, Postmus P, et al. Dose finding and sequencing study of paclitaxel and carboplatin non-small cell lung cancer. Semin Oncol 1995, 22(Suppl. 9), 78-122.
19. Akerley W, Choy H, Glantz M, et al. Phase II trial of weekly paclitaxel for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1997, 16, 161a.
20. Chang A, Boros L, Asbury R, Rubins J, Hui L. Weekly moderate-dose paclitaxel in stage FV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998, 17, A1806.
21. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologie study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997, 15, 187-192.
22. Seidman A, Murphy B, Hudes C, et al. Activity of taxol by weekly 1 hour infusion in patients with metastatic breast cancer: a phase II and pharmacologie study. Proc Am Soc Clin Oncol 1997, 16, 1480.
23. Georgiadis MS, Schuler BS, Kelley MJ, Johnson BE. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: preliminary results of a phase II trial in patients with advanced non-small cell lung cancer. Proc IASLC 1997, 18, A178.
24. Evans WK, Earle CC, Stuart DJ, et al. Phase II study of one-hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer. Lung Cancer 1997, 18, 83-94.
25. Jagasia M, Johnson DH, Hande KR, et al. Carboplatin and paclitaxel (1 and 24 hour infusion) in advanced non-small cell lung cancer: the results of sequential phase II studies. Proc Am Soc Clin Oncol 1997, 16, A1695.
26. Hainsworth JD, Thompson Urba WJ, Thompson KA, Hopkins LG, Greco FA. One-hour paclitaxel plus carboplatin in advanced non-small cell lung cancer (NSCLC): results of a Minnie Pearl cancer research network phase II study. Lung Cancer Abstracts, 8th World Conference on Lung Cancer 8/97, 18 (Suppl. 1), A81.
27. Johnson D, Zhu J, Schiller J, et al. E1594 -a randomized phase III trial in metastatic non-small cell lung cancer (NSCLC) - outcome of PS 2 patients: an Eastern Cooperative Oncology Group Trial. Proc Am Soc Clin Oncol 1999, 18, A1779.
28. Kelly K, Crowley J, Bunn P, Livingston R, Gandara D. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer: a Southwest Oncology Group Trial. Proc Am Soc Clin Oncol 1999, 18, A1777.